Anika Therapeutics (ANIK) Reaches $50.48 After 9.00% Up Move, Lacrosse Footwear (BOOT) Has 2.22 Sentiment

July 27, 2017 - By Adrian Erickson

The stock of Anika Therapeutics Inc (NASDAQ:ANIK) is a huge mover today! About 85,092 shares traded. Anika Therapeutics Inc (NASDAQ:ANIK) has risen 4.53% since July 27, 2016 and is uptrending. It has underperformed by 12.17% the S&P500.The move comes after 6 months positive chart setup for the $739.76M company. It was reported on Jul, 27 by Barchart.com. We have $55.02 PT which if reached, will make NASDAQ:ANIK worth $66.58 million more.

Boot Barn Holdings, Inc. is a lifestyle retailer of western and work-related footwear, apparel and accessories for men, women and children. The company has market cap of $176.84 million. The Company’s stores are located in or near neighborhood shopping centers with trade areas of approximately five or more miles, and it has opened stores in malls and outlet center locations. It has a 12.7 P/E ratio. The Company’s stores average an area of approximately 11,490 square feet and feature an assortment of brands and styles.

Ratings analysis reveals 33% of Boot Barn Holdings’s analysts are positive. Out of 3 Wall Street analysts rating Boot Barn Holdings, 1 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $15.0 while the high is $17.0. The stock’s average target of $16 is 140.60% above today’s ($6.65) share price. BOOT was included in 3 notes of analysts from November 14, 2016. The company was downgraded on Wednesday, November 30 by Robert W. Baird. The rating was upgraded by Citigroup to “Buy” on Monday, November 14. The firm earned “Neutral” rating on Thursday, December 15 by Mizuho.

Fs Capital Partners Vi Llc holds 100% of its portfolio in Boot Barn Holdings Inc for 13.44 million shares. Tyvor Capital Llc owns 144,311 shares or 0.73% of their US portfolio. Moreover, Manatuck Hill Partners Llc has 0.54% invested in the company for 88,800 shares. The Wisconsin-based Timpani Capital Management Llc has invested 0.47% in the stock. Stephens Investment Management Group Llc, a Texas-based fund reported 1.13 million shares.

About 10,983 shares traded. Boot Barn Holdings Inc (BOOT) has risen 24.96% since July 27, 2016 and is uptrending. It has outperformed by 8.26% the S&P500.

Since February 22, 2017, it had 0 insider purchases, and 3 selling transactions for $833,696 activity. On Wednesday, February 22 the insider Cheung Sylvia sold $196,096. 10,725 Anika Therapeutics Inc (NASDAQ:ANIK) shares with value of $508,274 were sold by Thompson Jeffery S. LAND RAYMOND J also sold $129,326 worth of Anika Therapeutics Inc (NASDAQ:ANIK) shares.

Investors sentiment decreased to 1.01 in 2016 Q4. Its down 0.25, from 1.26 in 2016Q3. It turned negative, as 17 investors sold Anika Therapeutics Inc shares while 53 reduced holdings. 20 funds opened positions while 51 raised stakes. 10.86 million shares or 0.92% less from 10.97 million shares in 2016Q3 were reported. Boston Advisors Llc, a Massachusetts-based fund reported 10,195 shares. Thompson Siegel Walmsley Limited Liability Company has invested 0.32% in Anika Therapeutics Inc (NASDAQ:ANIK). Louisiana State Employees Retirement Sys owns 5,900 shares or 0.01% of their US portfolio. Northern Trust invested 0% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK). Johnson Grp reported 0% stake. 27,462 are owned by Kbc Gp Nv. Royal National Bank & Trust Of Canada owns 37,763 shares. Oxford Asset Mgmt stated it has 0.14% in Anika Therapeutics Inc (NASDAQ:ANIK). Bnp Paribas Arbitrage Sa stated it has 4,491 shares. Credit Suisse Ag owns 21,315 shares for 0% of their portfolio. Washington Tru Comml Bank has 10 shares for 0% of their portfolio. 59,234 were accumulated by Fisher Asset. 250 are owned by Mcf Advsrs Limited Liability Company. Wells Fargo Mn reported 16,812 shares. Rhumbline Advisers has invested 0% in Anika Therapeutics Inc (NASDAQ:ANIK).

Anika Therapeutics, Inc. is an orthopedic medicines company. The company has market cap of $739.76 million. The Firm is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid technology. It has a 24.4 P/E ratio. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA scaffold to aid cartilage repair and regeneration.